Table 2.
Multivariate analysis of factors associated with herpes virus (CMV, EBV, and/or HHV6) infection/reactivation.
| Parameters | Percentage of CD4+CD25high lymphocytes | HLA mismatch | Anti-CMV IgG serostatus (D−/R+) | |
|---|---|---|---|---|
| Entire group, n = 99 | ||||
| Coefficient | −2.421 | 1.147 | 1.555 | |
| p value | 0.022 | 0.051 | 0.010 | |
| Odds ratio | 0.089 | 3.150 | 4.737 | |
| −95% Cl | −4.489 | −0.004 | 0.389 | |
| +95% Cl | −0.353 | 2.298 | 2.722 | |
| In vivo T cell-depleted group (patients receiving ATG or Campath), n = 73 | ||||
| Coefficient | −2.779 | 1.196 | 1.755 | |
| p value | 0.033 | 0.061 | 0.010 | |
| Odds ratio | 0.062 | 3.306 | 5.784 | |
| −95% Cl | 0.005 | 0.945 | 1.537 | |
| +95% Cl | 0.794 | 11.570 | 21.764 | |
* Table 2 shows the results of the forward stepwise logistic regression analysis. During the first step analysis, we included factors that had already been suggested [23,34,36,37,38,39] to contribute to the risk of herpes virus reactivation, including the type of donor (sibling or unrelated), the level of donor-recipient HLA matching (9/10 or less vs. 10/10 and sibling-matched transplantations), anti-CMV IgG serology (donor serology and donor/recipient serology: negative/positive), mode of transplantation (MAC vs. RIC), transplant material (peripheral blood progenitor cells (PBPCs) vs. bone marrow (BM)), and the percentages and numbers of CD4+ and CD4+CD25high lymphocytes.